- UHRA Home
- Browsing by Author
Browsing by Author "Naini, Vahid"
Now showing items 1-2 of 2
-
Erdafitinib in BCG-treated high risk non-muscle invasive bladder cancer
Catto, James W.F.; Tran, Ben; Roupret, Morgan; Gschwend, Juergen E.; Loriot, Yohann; Nishiyama, Hiroyuki; Redorta, Joan P.; Daneshmand, Siamak; Hussain, Syed A.; Cutuli, Hernan J; Procopio, Giuseppe; Guadalupi, Valentina; Vasdev, Nikhil; Naini, Vahid; Crow, Lauren; Triantos, Spyros; Baig, Mahadi; Steinberg, Gary D. (2024-01-30)Background: Treatment options are limited for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with disease recurrence after bacillus Calmette–Guérin (BCG) treatment and who are ineligible for/refuse ... -
Phase 2 Study of the Efficacy and Safety of Erdafitinib in Patients With Bacillus Calmette-Guérin (BCG)-Unresponsive, High-Risk Non–Muscle-Invasive Bladder Cancer (HR-NMIBC) With FGFR3/2 Alterations (alt) in THOR-2: Cohort 2 Interim Analysis Results
Catto, James W.F.; Tran, Ben; Master, Viraj A.; Roupret, Morgan; Pignot, Geraldine; Tubaro, Andrea; Shimizu, Nobuaki; Vasdev, Nikhil; Gschwend, Juergen; Loriot, Yohann; Nishiyama, Hiyoyuki; Redorta, Joan; Daneshmand, Siamak; Miura, Yuji; Naini, Vahid; Crow, Lauren; Triantos, Spyros; Baig, Mahadi; Steinberg, Gary D. (2023-02-17)Patients presenting with NMIBC carcinoma in situ (CIS) have a high risk of progression1,2FGFR inhibition may benefit patients with CIS with FGFRalt who are unresponsive to fi rst-line BCG, for whom treatment options, other ...